Chart-Typ:
Zeitraum:
| QIAGEN Agrees To EQT Takeover Offer For All Outstanding Shares At €46.50/share | WASHINGTON (dpa-AFX) - Qiagen N.V. (QGEN) on Wednesday said it has agreed to an all-cash takeover offer by EQT Private Equity at €46.50 per share, valuing the company at approximately €10.8... ► Artikel lesen |
| QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer | QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
Click here for more information.STOCKHOLM, Oct. 21, 2026 /PRNewswire/ -- With this investment... ► Artikel lesen |
| Finanzinvestor EQT übernimmt Qiagen - Bewertung 10,8 Milliarden Euro | DJ Finanzinvestor EQT übernimmt Qiagen - Bewertung 10,8 Milliarden Euro
DOW JONES--Das im DAX notierte Diagnostikunternehmen Qiagen wird übernommen. Der Konzern hat sich mit dem schwedischen Finanzinvestor... ► Artikel lesen |
| Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen |
| Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen |
| Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen |
| Enliven Therapeutics, Inc.: Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia | Enliven remains on track to initiate ENABLE-2 before year-end 2026
BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company)... ► Artikel lesen |
| Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.